COT:CA - Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
COT:CA - Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
LONDON, ONTARIO--(Marketwire - July 2, 2009) - Critical Outcome Technologies Inc. (TSX VENTURE:COT), announced positive results today from combination agent animal experiments carried out at a prominent American cancer research facility. The results provide strong supportive evidence for the continued evaluation of COTI-2 in combination with conventional single agent therapy for the treatment of ovarian cancer:
- Tumor growth inhibition was significantly greater in the COTI-2 plus Doxil treated animals compared to the Doxil control group treated animals with:
-- 2mg/kg Doxil control causing 29% tumor growth inhibition
- The effectiveness of the combination treatments with COTI-2 was apparent early in the study (day 4) and increased throughout the remainder of the study.
- Combination treatments were well tolerated.
"We are delighted to see that intravenous COTI-2 in combination with Doxil showed superior treatment results compared to Doxil alone as measured by significant tumor growth inhibition in an animal model of an aggressive human ovarian cancer (A2780). These results are significant because they add to the impressive data set of COTI-2, showing effectiveness, particularly in combination with first and second line agents, against multiple cancers and low toxicity," said Dr. Wayne Danter, President and Chief Scientific Officer of Critical Outcome Technologies Inc. (COTI).
"COTI will share this new data with parties who have expressed interest in a commercial partnership related to COTI-2," said Mr. Michael Cloutier, Chief Executive Officer of COTI.
The Company intends to repeat this study using an oral formulation of COTI-2 to compare the effectiveness of oral COTI-2 in an animal model of human disease.
The Company is also advising of a correction to its June 10, 2009 press release, which announced a brokered private placement as this should have read a non-brokered private placement.
About Critical Outcome Technologies Inc. (COTI)
COTI is formed around a unique computational platform technology called CHEMSAS(R), which allows for the accelerated identification, profiling and optimization of targeted small molecules potentially effective in the treatment of human diseases for which current therapy is either lacking or ineffective. COTI's business is focused on the discovery and preclinical development of libraries of novel, optimized lead molecules for the treatment of specific cancers, HIV and multiple sclerosis. Currently, five targeted libraries of lead compounds are under active development: small cell lung cancer, HIV integrase inhibitors, acute adult leukemia, multiple sclerosis and colorectal cancer.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Source: Marketwire Canada (July 2, 2009 - 10:29 AM EDT)
COT:CA - Intravenous COTI-2 in Combination with Doxil(R) (Doxorubicin HCl) is More Effective Than Treatment with Doxil Alone in an Animal Model of Human Ovarian Cancer
Linear Mode
